Related references
Note: Only part of the references are listed.Long-term remission and biologic persistence rates: 12-year real-world data
Kieran Murray et al.
ARTHRITIS RESEARCH & THERAPY (2021)
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis
Andreas Kerschbaumer et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel -group, randomised, active-controlled, phase 3b trial
Iain B. McInnes et al.
LANCET (2020)
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
Laure Gossec et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate
Leonieke J. J. van Mens et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
New Guidelines for Statistical Reporting in the Journal
David Harrington et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis
Lazaros I. Sakkas et al.
FRONTIERS IN PHARMACOLOGY (2019)
Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor
Alexis Ogdie et al.
JOURNAL OF RHEUMATOLOGY (2019)
Evolution of psoriatic arthritis study patient population characteristics in the era of biological treatments
Ann-Sophie Vandendorpe et al.
RMD OPEN (2019)
Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
Ennio Lubrano et al.
RHEUMATOLOGY AND THERAPY (2019)
Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature
Laure Gossec et al.
JOURNAL OF RHEUMATOLOGY (2018)
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study
Philip Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Effectiveness and safety of ustekinumab in na⟨ve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study
Maria Sole Chimenti et al.
CLINICAL RHEUMATOLOGY (2018)
Psoriatic arthritis: tissue-directed inflammation?
Giacomo Cafaro et al.
CLINICAL RHEUMATOLOGY (2018)
Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE)
Florenzo Iannone et al.
CLINICAL RHEUMATOLOGY (2018)
Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review
Ross J. Thibodaux et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2018)
Minimal Disease Activity and Patient-Acceptable Symptom State in Psoriatic Arthritis: A Real-World Evidence Study With Ustekinumab
Ruben Queiro et al.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2018)
Psoriatic arthritis 1 The pathogenesis of psoriatic arthritis
Douglas J. Veale et al.
LANCET (2018)
Psoriatic arthritis 2 Clinical management of psoriatic arthritis
Filip Van den Bosch et al.
LANCET (2018)
Ustekinumab in psoriatic arthritis: need for studies from real-world evidence
Ruben Queiro et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2018)
Novel Concepts in Psoriatic Arthritis Management: Can W Treat to Target?
Laura J. Tucker et al.
CURRENT RHEUMATOLOGY REPORTS (2018)
Validation of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire and its potential as a single-item outcome measure in clinical practice
Richard Holland et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression
D. Aletaha et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Treatment with ustekinumab in a Spanish cohort of patients with psoriasis and psoriatic arthritis in daily clinical practice
Miriam Almirall et al.
CLINICAL RHEUMATOLOGY (2017)
Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis Results Through Week Twenty-Four of the GO-VIBRANT Study
Arthur Kavanaugh et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study
Maddalena Napolitano et al.
CLINICAL RHEUMATOLOGY (2017)
Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score
Monika M. Schoels et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Defining Low Disease Activity States in Psoriatic Arthritis using Novel Composite Disease Instruments
Laura C. Coates et al.
JOURNAL OF RHEUMATOLOGY (2016)
Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study
Josef S. Smolen et al.
LANCET (2016)
Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis
Roberta Lupoli et al.
ARTHRITIS RESEARCH & THERAPY (2016)
Cardiovascular risk factors influence response to biological therapies in psoriasis
Ana Batalla et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
When do confounding by indication and inadequate risk adjustment bias critical care studies? A simulation study
Michael W. Sjoding et al.
CRITICAL CARE (2015)
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double- blind randomised placebo- controlled study (RAPID-PsA)
P. J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
Christopher Ritchlin et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
Iain B. McInnes et al.
LANCET (2013)
Treatment Response, Drug Survival, and Predictors Thereof in 764 Patients With Psoriatic Arthritis Treated With Anti-Tumor Necrosis Factor α Therapy Results From the Nationwide Danish DANBIO Registry
Bente Glintborg et al.
ARTHRITIS AND RHEUMATISM (2011)
Time and predictors of response to tumour necrosis factor-α blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort
Lihi Eder et al.
RHEUMATOLOGY (2010)
Measuring clinical enthesitis in psoriatic arthritis: Assessment of existing measures and development of an instrument specific to psoriatic arthritis
Paul J. Healy et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
Classification criteria for psoriatic arthritis - Development of new criteria from a large international study
William Taylor et al.
ARTHRITIS AND RHEUMATISM (2006)
Share Paper
